Alessandro Grottesi

Dr. Alessandro Grottesi


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Neurobiology of Disease
Verified
Journal Article
Closed access
FSFederico Sicca
Federico Sicca
PIpaola imbrici
paola imbrici
Maria Cristina D'AdamoMaria Cristina D'Adamo
Maria Cristina D'Adamo
FMFrancesca Moro
Francesca Moro
FBFabrizia Bonatti
Fabrizia Bonatti
MPMauro Pessia
Mauro Pessia

15 October 2003 in FEBS Letters
Verified
Journal Article
Closed access
OBOliver Beckstein
Oliver Beckstein
PBPhilip Biggin
Philip Biggin
PBPeter Bond
Peter Bond
JBJoanne N Bright
Joanne N Bright
Carmen DomeneCarmen Domene
Carmen Domene
MSMark Sansom
Mark Sansom

1 January 2000 in The Journal of Chemical Physics
Verified
Journal Article
Closed access
PDF file
AAAndrea Amadei
Andrea Amadei
GCGiovanni Chillemi
Giovanni Chillemi
MCM. A. Ceruso
M. A. Ceruso
AGAlessandro Grottesi
Alessandro Grottesi
ANA. Di Nola
A. Di Nola
From a specific definition of the roto-translational (external) and intramolecular (internal) coordinates, a constrained dynamics algorithm is derived for removing the roto-translational motions during molecular dynamics simulations, within the leap-frog integration scheme. In the paper the theoretical basis of this new method and its statistical mechanical consistency are reported, together with two applications.

27 March 2008 in Human Molecular Genetics
Verified
Journal Article
Closed access
SMSimone Martinelli
Simone Martinelli
PTPaola Torreri
Paola Torreri
MTMichele Tinti
Michele Tinti
Lorenzo StellaLorenzo Stella
Lorenzo Stella
Gianfranco BocchinfusoGianfranco Bocchinfuso
Gianfranco Bocchinfuso
MTMarco Tartaglia
Marco Tartaglia
Missense PTPN11 mutations cause Noonan and LEOPARD syndromes (NS and LS), two developmental disorders with pleiomorphic phenotypes. PTPN11 encodes SHP2, an SH2 domain-containing protein tyrosine phosphatase functioning as a signal transducer. Generally, different substitutions of a particular amino acid residue are observed in these diseases, indicating that the crucial factor is the residue being replaced. For a few codons, only one substitution is observed, suggesting the possibility of specific roles for the residue introduced. We analyzed the biochemical behavior and ligand-binding properties of all possible substitutions arising from single-base changes affecting codons 42, 139, 279, 282 and 468 to investigate the mechanisms underlying the invariant occurrence of the T42A, E139D and I282V substitutions in NS and the Y279C and T468M changes in LS. Our data demonstrate that the isoleucine-to-valine change at codon 282 is the only substitution at that position perturbing the stability of SHP2's closed conformation without impairing catalysis, while the threonine-to-alanine change at codon 42, but not other substitutions of that residue, promotes increased phosphopeptide-binding affinity. The recognition specificity of the C-SH2 domain bearing the E139D substitution differed substantially from its wild-type counterpart acquiring binding properties similar to those observed for the N-SH2 domain, revealing a novel mechanism of SHP2's functional dysregulation. Finally, while functional selection does not seem to occur for the substitutions at codons 279 and 468, we point to deamination of the methylated cytosine at nucleotide 1403 as the driving factor leading to the high prevalence of the T468M change in LS.

2 May 2014 in Human Molecular Genetics
Verified
Journal Article
Open access
EAElena Ambrosini
Elena Ambrosini
FSFederico Sicca
Federico Sicca
MBMARIA STEFANIA BRIGNONE
MARIA STEFANIA BRIGNONE
Maria Cristina D'AdamoMaria Cristina D'Adamo
Maria Cristina D'Adamo
CNCarlo Napolitano
Carlo Napolitano
MPMauro Pessia
Mauro Pessia
Short QT3 syndrome (SQT3S) is a cardiac disorder characterized by a high risk of mortality and associated with mutations in Kir2.1 (KCNJ2) channels. The molecular mechanisms leading to channel dysfunction, cardiac rhythm disturbances and neurodevelopmental disorders, potentially associated with SQT3S, remain incompletely understood. Here, we report on monozygotic twins displaying a short QT interval on electrocardiogram recordings and autism-epilepsy phenotype. Genetic screening identified a novel KCNJ2 variant in Kir2.1 that (i) enhanced the channel's surface expression and stability at the plasma membrane, (ii) reduced protein ubiquitylation and degradation, (iii) altered protein compartmentalization in lipid rafts by targeting more channels to cholesterol-poor domains and (iv) reduced interactions with caveolin 2. Importantly, our study reveals novel physiological mechanisms concerning wild-type Kir2.1 channel processing by the cell, such as binding to both caveolin 1 and 2, protein degradation through the ubiquitin-proteasome pathway; in addition, it uncovers a potential multifunctional site that controls Kir2.1 surface expression, protein half-life and partitioning to lipid rafts. The reported mechanisms emerge as crucial also for proper astrocyte function, suggesting the need for a neuropsychiatric evaluation in patients with SQT3S and offering new opportunities for disease management.

1 July 1999 in Biochemistry
Verified
Journal Article
Closed access
Sonia MelinoSonia Melino
Sonia Melino
SRStefano Rufini
Stefano Rufini
MSMarco Sette
Marco Sette
RMRoberto Morero
Roberto Morero
AGAlessandro Grottesi
Alessandro Grottesi
RPRaffaele Petruzzelli
Raffaele Petruzzelli